製品番号: HY-15349

Trovirdine

(別名: LY300046)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.62%
CAS 番号: 149488-17-5
分子式: C₁₃H₁₃BrN₄S
分子量:337.24

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Trovirdine 構造式

CAS 番号: 149488-17-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate. IC50 value: 7 nM Target: HIV-1 Trovirdine is currently in phase I clinical trials for potential use in thetreatment of AIDS.

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	EC₅₀	0.015 μM Compound: trovirdine	Antiviral activity against HIV1 in human C8166 cells assessed as reduction of p24 antigen level Antiviral activity against HIV1 in human C8166 cells assessed as reduction of p24 antigen level	[PMID: 18226532]
H9	IC₅₀	0.02 μM Compound: Trovirdine	Inhibitory activity against multidrug resistant HIV-1 strain RT-MDR Inhibitory activity against multidrug resistant HIV-1 strain RT-MDR	[PMID: 10999473]
MT4	CC₅₀	60 μM Compound: Trovirdine	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% was determined by MTT method Concentration required to reduce the viability of mock-infected MT-4 cells by 50% was determined by MTT method	[PMID: 12593657]
MT4	EC₅₀	0.02 μM Compound: Trovirdine	Concentration required to achieve 50% protection of MT-4 cell from the HIV-1 induced cytopathogenicity was determined by the MTT method Concentration required to achieve 50% protection of MT-4 cell from the HIV-1 induced cytopathogenicity was determined by the MTT method	[PMID: 12593657]
MT4	CC₅₀	60 μM Compound: trovirdine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18226532]
MT4	EC₅₀	0.02 μM Compound: trovirdine	Antiretroviral activity against HIV1 in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiretroviral activity against HIV1 in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 18226532]
MT4	CC₅₀	60 μM Compound: trovirdine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 18226533]
MT4	EC₅₀	0.02 μM Compound: trovirdine	Antiviral activity against HIV1 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18226533]
MT4	CC₅₀	60 μM Compound: trovirdine	Cytotoxicity against human MT4 cells by MTT method Cytotoxicity against human MT4 cells by MTT method	[PMID: 18502646]
MT4	EC₅₀	0.02 μM Compound: trovirdine	Antiviral activity against HIV1 in MT4 cells assessed as reduction of virus induced cytopathogenicity by MTT method Antiviral activity against HIV1 in MT4 cells assessed as reduction of virus induced cytopathogenicity by MTT method	[PMID: 18502646]
MT4	CC₅₀	60 μM Compound: Trovirdine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 18954921]
MT4	EC₅₀	0.02 μM Compound: Trovirdine	Antiviral activity against wild type HIV1 3B in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay Antiviral activity against wild type HIV1 3B in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay	[PMID: 18954921]
MT4	EC₅₀	15 μM Compound: Trovirdine	Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay	[PMID: 18954921]
MT4	CC₅₀	60 μM Compound: Trovirdine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19058881]
MT4	EC₅₀	0.02 μM Compound: Trovirdine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19058881]
MT4	EC₅₀	0.12 μM Compound: Trovirdine	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19058881]
MT4	ED₅₀	0.02 μM Compound: LY-300046	Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells	[PMID: 8863804]
MT4	ED₅₀	>5 μM Compound: Trovirdine	Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	ED₅₀	0.8 μM Compound: Trovirdine	Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	CC₅₀	60 μM Compound: Trovirdine	Cytotoxicity against mock infected Homo sapiens (human) MT4 cells assessed as cell viability by MTT assay Cytotoxicity against mock infected Homo sapiens (human) MT4 cells assessed as cell viability by MTT assay	10.1007/s00044-009-9192-x
MT4	EC₅₀	0.02 μM Compound: Trovirdine	Antiviral activity against wild type Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-009-9192-x

化学情報

CAS 番号 149488-17-5
性状 Solid
分子量 337.24
分子式 C₁₃H₁₃BrN₄S
Color White to off-white
SMILES

S=C(NCCC1=NC=CC=C1)NC2=NC=C(Br)C=C2
別名

LY300046
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (296.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9652 mL

14.8262 mL

29.6525 mL

5 mM

0.5930 mL

2.9652 mL

5.9305 mL

10 mM

0.2965 mL

1.4826 mL

2.9652 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (268 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhang, H. et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethylthiazolyl thiourea derivatives trovirdine and MSC-127.

[2]. Cantrell, A.S. et al. Phenethylthiazolylthiourea (PETT) compounds as a newclass of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9652 mL	14.8262 mL	29.6525 mL	74.1312 mL
	5 mM	0.5930 mL	2.9652 mL	5.9305 mL	14.8262 mL
	10 mM	0.2965 mL	1.4826 mL	2.9652 mL	7.4131 mL
	15 mM	0.1977 mL	0.9884 mL	1.9768 mL	4.9421 mL
	20 mM	0.1483 mL	0.7413 mL	1.4826 mL	3.7066 mL
	25 mM	0.1186 mL	0.5930 mL	1.1861 mL	2.9652 mL
	30 mM	0.0988 mL	0.4942 mL	0.9884 mL	2.4710 mL
	40 mM	0.0741 mL	0.3707 mL	0.7413 mL	1.8533 mL
	50 mM	0.0593 mL	0.2965 mL	0.5930 mL	1.4826 mL
	60 mM	0.0494 mL	0.2471 mL	0.4942 mL	1.2355 mL
	80 mM	0.0371 mL	0.1853 mL	0.3707 mL	0.9266 mL
	100 mM	0.0297 mL	0.1483 mL	0.2965 mL	0.7413 mL

Keywords

Trovirdine

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Trovirdine

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

MedChemExpress（MCE）の使用を引用している文献 Trovirdine

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Trovirdine

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

MedChemExpress（MCE）の使用を引用している文献 Trovirdine

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Trovirdine 関連分類

HY-15349 関連分類